TY - JOUR
T1 - Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation
T2 - A comparison between multiparameter flow cytometry and Wilms' tumor 1 expression
AU - Rossi, Giovanni
AU - Carella, Angelo Michele
AU - Minervini, Maria Marta
AU - di Nardo, Francesco
AU - Waure, Chiara de
AU - Greco, Michele Mario
AU - Merla, Emanuela
AU - Cillis, Giovanni Pio de
AU - Di Renzo, Nicola
AU - Melpignano, Angela
AU - Capalbo, Silvana
AU - Palumbo, Gaetano
AU - Pisapia, Giovanni
AU - Cascavilla, Nicola
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Minimal residual disease (MRD) of 30 adult AML patients was monitored by multiparameter flow cytometry (MFC) and WT1 expression before and after allogeneic stem cell transplantation (allo-SCT). Diagnostic performance of pre-transplant MRD measured by MFC was higher than that obtained by WT1 expression. Comparable results were displayed at day +30 post-transplant, while better values by WT1 compared to MFC were found at day +90. Positive MRD by MFC predicted a shorter disease free survival (DFS) before and 1 month after transplant (p= 0.006 and p= 0.005), while only high WT1 levels at 1 month from the transplant significantly impacted on DFS (p= 0.010). Our results support the idea that MRD monitoring by MFC should be suggested before and 30 days after the transplant, while WT1 expression should be preferred after this procedure. The assessment of MRD at day +30 from allo-SCT is recommended as post transplant check-point for the predictive role displayed, independently of the method used.
AB - Minimal residual disease (MRD) of 30 adult AML patients was monitored by multiparameter flow cytometry (MFC) and WT1 expression before and after allogeneic stem cell transplantation (allo-SCT). Diagnostic performance of pre-transplant MRD measured by MFC was higher than that obtained by WT1 expression. Comparable results were displayed at day +30 post-transplant, while better values by WT1 compared to MFC were found at day +90. Positive MRD by MFC predicted a shorter disease free survival (DFS) before and 1 month after transplant (p= 0.006 and p= 0.005), while only high WT1 levels at 1 month from the transplant significantly impacted on DFS (p= 0.010). Our results support the idea that MRD monitoring by MFC should be suggested before and 30 days after the transplant, while WT1 expression should be preferred after this procedure. The assessment of MRD at day +30 from allo-SCT is recommended as post transplant check-point for the predictive role displayed, independently of the method used.
KW - Acute myeloid leukemia
KW - Allogeneic stem cell transplantation
KW - Minimal residual disease
KW - Multiparameter flow cytometry
KW - WT1 expression
UR - http://www.scopus.com/inward/record.url?scp=84921436191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921436191&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2014.11.011
DO - 10.1016/j.leukres.2014.11.011
M3 - Article
C2 - 25498507
AN - SCOPUS:84921436191
VL - 39
SP - 138
EP - 143
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 2
ER -